Corcept Therapeutics Inc (NASDAQ: CORT) has reported earnings for its fourth fiscal quarter (ending December 31) of $0.29 versus $0.30 for the same period a year ago — a decline of -3%. For the latest four quarters through December 31, E.P.S. were $1.35 versus $1.02 for the same period a year ago — an increase of 32%.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock enjoyed a large increase of 3.5% on 2/26/25. The stock closed at $63.37. Moreover, trading volume in this advance was above average at 144% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -12.7% during the last week.
Current PriceTarget Research Rating
Corcept Therapeutics has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Corcept Therapeutics has a poor Appreciation Score of 26 but a very high Power Rating of 94, with the High Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment